OCT 09, 2018 02:16 PM PDT

Pharmacological Manipulation of a Brain-Signaling Mechanism Reverses An Autism-Related Pathway

WRITTEN BY: Nouran Amin

According to a study published in the Proceedings of the National Academy of Sciences (PNAS), researchers at Florida Atlantic University have discovered a way to reverse an autism-related pathway in genetically engineered mice by pharmacologically manipulating a brain-signaling pathway.

Image via EverydayHealth

Using an investigational drug to target a brain-signaling pathway, scientists were able to normalize the disrupted physiology and behaviors of mice. Additionally, these effects were also observed in adult mice suggesting a possible therapeutic drug to treat adults with autism spectrum disorder (ASD).

Presently, no FDA-approved medications that improve the core symptoms of ASD are in existence. However, the research study may bring new hope in developing a drug based on a novel approach that targets an enzyme involved in stress and inflammation. The research was motivated by decades of studies on the mood-regulating hormone—serotonin which regulates many brain synapses that are the gaps between nerve cells.

Serotonin is dependent on another protein called serotonin transporter (SERT), which regulates the level of serotonin. Multiple studies show that changes in SERT expression and function may be implicated in neuropsychiatric disorders, such as ASD.

"We suspected that normally as serotonin signaling changes, neurons turn up or down the activity of this transporter keeping serotonin levels finely balanced," says Randy Blakely, Ph.D., senior author, executive director of FAU's Brain Institute. “We generated evidence for this idea using cultured cells that expressed SERT, but what these observations meant for the brain or brain disorders was unclear. Our years of studying SERT gave us a clue as to how to tone down SERT hyperactivity without eliminating the protein's normal function.”

Additionally, Blakely and research team previously discovered an enzyme that may serve as a key SERT regulator. The enzyme is called p38α MAPK and is well known to contribute to inflammatory responses. When researchers genetically engineered an Ala56 mutation into the genome of a mouse, observations were noted regarding where brain biochemistry, physiology and behavior—as predicted, SERT was found to be high by p38α MAPK. "The studies primarily told us that Ala56 wasn't a benign mutation and possibly that the mice might provide a testbed for developing novel serotoninergic medications," said Blakely.

Relatively rare, the SERT Ala56 mutation occurs in about 1 percent of the U.S. population. Despite the research on human studies that found the DNA change is related to traits of ASD, others who carried the mutation did not exhibit any symptoms of ASD. "We don't think the variant is a cause for ASD in many people; only in those where other genetic or environmental changes have occurred. The bigger message is that serotonin's role in brain disorders likely goes far beyond depression," said Blakely. "Even though the first connections between serotonin and ASD were made more than 50 years ago, how we might tap into these observations for potential treatments hasn't been clear. We think our study suggests a new direction for medication development, particularly if we can identify those patients where changes in brain serotonin make a difference."

Source: Proceedings of the National Academy of Science (PNAS), Florida Atlantic University

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 07, 2018
Drug Discovery
AUG 07, 2018
Improving Liver Cancer Therapy
According to studies conducted in the United States, the ninth leading causes of cancer deaths is hepatocellular carcinoma, the primary cancer of the liver...
AUG 21, 2018
Drug Discovery
AUG 21, 2018
Genetic Regulators of Regeneration Bring Hope for Drug Discovery
Portions of DNA that do not seem to have a function are referred to as “junk”. Now, according to a study published in Regenerative Medicine, re...
AUG 28, 2018
Drug Discovery
AUG 28, 2018
Drug Reduced Recurrent Ventricular Tachycardia
A common drug used to treat chest pain, known as ranolazine and branded as Ranexa®, was found to be safe in a clinical study of more than 1,000 patient...
SEP 30, 2018
Drug Discovery
SEP 30, 2018
Vitamin D May Decrease Childhood Obesity
According to research presented in the in Annual European Society for Pediatric Endocrinology, vitamin D supplements may encourage weight loss and reduce t...
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Immunotherapeutic Targets A Blood-Clotting Protein
Fibrin is a blood protein that normally does not cross to the brain, however, several neurological disorders have a defect in the blood-brain barrier that ...
NOV 25, 2018
Drug Discovery
NOV 25, 2018
'Longevity protein' Improves Healing in Aging Muscles
A downside to aging is that the skeletal muscles lose their ability to heal after muscle injury. However, a recent research study at the University of Pitt...
Loading Comments...